公开(公告)号：US11891435B2

公开(公告)日：2024-02-06

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish Agrawal ,  Kevin Graham ,  Agnes Eva Hamburger ,  Christopher Mohr ,  Derek E. Piper ,  Kenneth William Walker ,  Zhulun Wang ,  Cen Xu

IPC: C07K16/00 ,  A61K39/395 ,  A61K39/00 ,  A61K49/00 ,  A61K49/16 ,  C12P21/08 ,  G01N33/53 ,  C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22 ,  A61K47/68 ,  A61K38/17 ,  A61K51/10 ,  C07K14/575 ,  C07K16/26 ,  C07K14/72 ,  C07K14/47 ,  G01N33/74 ,  G01N33/68

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K38/1796 ,  A61K38/22 ,  A61K47/6843 ,  A61K47/6849 ,  A61K51/10 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2300/00 ,  C07K14/47 ,  C07K14/575 ,  C07K14/57563 ,  C07K14/72 ,  C07K16/00 ,  C07K16/26 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C12N2501/30 ,  G01N33/6854 ,  G01N33/6896 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5757 ,  Y02A50/30

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US10053507B2

公开(公告)日：2018-08-21

申请号：US15592115

申请日：2017-05-10

Applicant: AMGEN INC.

Inventor： Cen Xu ,  Agnes Eva Hamburger

IPC: A61K35/12 ,  A61K39/00 ,  C07K16/28

CPC classification number: C07K16/28 ,  A61P25/06 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

公开(公告)号：US09862752B2

公开(公告)日：2018-01-09

申请号：US14908459

申请日：2014-07-31

Applicant: Amgen Inc.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Z. Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Marissa Mock ,  Kenneth Walker

IPC: C07K14/00 ,  C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US09676851B2

公开(公告)日：2017-06-13

申请号：US14775995

申请日：2014-03-14

Applicant: AMGEN INC.

Inventor： Cen Xu ,  Agnes Eva Hamburger

IPC: A61K35/12 ,  A61K39/00 ,  C07K16/28

CPC classification number: C07K16/28 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

公开(公告)号：US09365653B2

公开(公告)日：2016-06-14

申请号：US14304559

申请日：2014-06-13

Applicant: AMGEN INC.

Inventor： Cen Xu ,  Agnes Eva Hamburger

IPC: C07K16/28

CPC classification number: C07K16/28 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.

Abstract translation: 提供了结合人PAC1的抗体及其抗原结合片段。 还提供了编码抗体及其抗原结合片段，载体和编码其的细胞的核酸。 抗体及其抗原结合片段可以抑制PAC1与PACAP的结合，并且可用于许多PAC1相关疾病，包括治疗和/或预防头痛障碍，包括偏头痛。

公开(公告)号：US09273106B2

公开(公告)日：2016-03-01

申请号：US14134482

申请日：2013-12-19

Applicant: Amgen Inc.

Inventor： Edward John Belouski ,  Murielle Marie Ellison ,  Agnes Eva Hamburger ,  Randy Ira Hecht ,  Yue-Sheng Li ,  Mark Leo Michaels ,  Jeonghoon Sun ,  Jing Xu

IPC: A61K38/18 ,  C07K14/50 ,  C12N15/12 ,  C12N15/63 ,  C07K16/18 ,  A61K38/00

CPC classification number: C07K14/50 ,  A61K38/00 ,  A61K38/1825 ,  A61K2039/505 ,  C07K16/18 ,  C07K2319/30

Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.

Abstract translation: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。

公开(公告)号：US20140378665A1

公开(公告)日：2014-12-25

申请号：US14374885

申请日：2013-01-28

Applicant: AMGEN INC.

Inventor： Yumei Xiong ,  Yi Zhang ,  Jackie Zeqi Sheng ,  Agnes Eva Hamburger ,  Murielle Veniant-Ellison ,  Grant Shimamoto ,  Xiaoshan Min ,  Zhulun Wang ,  Jie Tang ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Bryan Lemon

IPC: C07K14/475

CPC classification number: C07K14/475 ,  A61K39/0005 ,  A61K2039/6056 ,  C07K2319/30

Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Abstract translation: 提供GDF15多肽，包含GDF15的构建体及其突变体。 在各种实施方案中，GDF15多肽，包含GDF15的构建体及其突变体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。